Insulet and Ypsomed have entered into an exclusive agreement for the distribution of the OmniPod Insulin Management System in nine countries across Europe, as well as China and Australia.

As per the agreement, Ypsomed will have the exclusive right to promote, advertise, market, distribute and sell the OmniPod System in 11 countries covered by the agreement, beginning in Germany, France and the UK in June 2010.

Ypsomed expects to introduce the OmniPod System to Switzerland, the Netherlands, Belgium, the Nordic countries and Australia in the second half of 2010, and in China in the first half of 2011.

Duane DeSisto, president and chief executive officer of Insulet, said: “Since gaining our CE Mark approval last year, we have been thrilled with the level of interest in distributing the OmniPod System outside of the US. After an extensive review, we chose Ypsomed as our partner to bring the OmniPod System to key international markets because of their 25 year track record as a distributor and technology provider of insulin pumps, blood glucose meters and diabetes care supplies.

“Ypsomed’s proven expertise and established infrastructure in serving the diabetes community, best positions us to maximize the international opportunity for the OmniPod System.”

Simon Michel, senior vice president of marketing and sales at Ypsomed, said: “We at Ypsomed are excited and proud to have been selected by Insulet as their exclusive distribution partner for the OmniPod System.

“We are motivated to launch the OmniPod System in Europe and other countries around the world under the mylife diabetes care brand. The OmniPod System is an innovative and attractive extension to our mylife product portfolio. We expect that over 200 Ypsomed employees will be involved in the promotion, marketing, distribution and sale of the OmniPod System.”